Filing Flows › Fate Therapeutics (FATE) › Q1 2025
Fate Therapeutics (FATE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Fate Therapeutics (FATE) reported revenue of $1.6M for the first quarter 2025 (Q1 2025), -15% from a year earlier and -12% from the quarter before.
Fate Therapeutics, Q1 2025: revenue $1.6M (-15% year over year), net loss $37.6M, operating cash flow −$33.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -12% | -15% |
| Operating profit | −$41.3M | — | — |
| Net earnings | −$37.6M | — | — |
| Operating cash flow | −$33.8M | — | — |
What changed
Revenue was $1.6M in Q1 2025, down 15% year over year and down 12% from the previous quarter.
Operating costs exceeded revenue by $41.3M, an operating margin of -2534.1%. Total costs fell 19% while revenue fell 15%. The quarter ended with a net loss of $37.6M, narrower than the previous quarter's $52.2M loss.
Operating cash flow was −$33.8M. Non-cash charges added back $3.3M of depreciation and amortization and $7.4M of share-based compensation. Working capital and other items used $6.9M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$35.0M.
Questions
What was Fate Therapeutics' revenue in the first quarter 2025?
Fate Therapeutics (FATE) reported revenue of $1.6M for the first quarter 2025 (Q1 2025), -15% from a year earlier and -12% from the quarter before.
Source: Fate Therapeutics 10-Q on SEC EDGAR.